A new therapeutic strategy against hormone-dependent breast cancer: The preclinical development of a dual aromatase and sulfatase inhibitor

Clinical Cancer Research

Volumn 14, Issue 20, 2008, Pages 6469-6477

  Foster, Paul A ^a   Chander, Surinder K ^a   Newman, Simon P ^a   Woo, L W Lawrence ^b   Sutcliffe, Oliver B ^b   Bubert, Christian ^b   Zhou, Dujin ^c   Chen, Shiuan ^c   Potter, Barry V L ^b   Reed, Michael J ^a   Purohit, Atul ^a  

^a ST MARY S HOSPITAL   (United Kingdom)

^b UNIVERSITY OF BATH   (United Kingdom)

^c CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROSTENEDIONE; AROMATASE INHIBITOR; COMPLEMENTARY DNA; ENZYME INHIBITOR; ESTRADIOL; LETROZOLE; STERYL SULFATASE; STX 64; STX 681; SULFATASE; UNCLASSIFIED DRUG; AZASTEROID; ESTROGEN; NITRILE; STX 213; TRIAZOLE DERIVATIVE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BREAST CANCER; CANCER GROWTH; CARCINOGENESIS; CELL PROLIFERATION; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DRUG INHIBITION; DRUG STRUCTURE; DRUG SYNTHESIS; ENZYME INHIBITION; FEMALE; HORMONE BLOOD LEVEL; HORMONE DEPENDENCE; HORMONE STRUCTURE; HORMONE SYNTHESIS; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; OVARIECTOMY; PRIORITY JOURNAL; PROTEIN EXPRESSION; ANIMAL; BLOOD; BREAST TUMOR; DRUG ANTAGONISM; DRUG EFFECT; DRUG SCREENING; ENZYMOLOGY; HUMAN; METABOLISM; NEOPLASM; NUDE MOUSE; ORAL DRUG ADMINISTRATION; RAT; TREATMENT OUTCOME; TUMOR CELL CULTURE; WISTAR RAT;

ADMINISTRATION, ORAL; ANIMALS; AROMATASE INHIBITORS; AZASTEROIDS; BREAST NEOPLASMS; CELL PROLIFERATION; ESTROGENS; FEMALE; HUMANS; MICE; MICE, NUDE; NEOPLASMS, HORMONE-DEPENDENT; NITRILES; OVARIECTOMY; RATS; RATS, WISTAR; STERYL-SULFATASE; TREATMENT OUTCOME; TRIAZOLES; TUMOR CELLS, CULTURED; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 58149198589     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-08-1027     Document Type: Article

References (49)

1. Cole MP, Jones CTA,Todd IDH. A new antiestrogenic agent in late breast cancer. An early clinical appraisal of lCI 46,474. Br J Cancer 1971;25:270-5.
2. Smith IE, Dowsett M. Aromatase inhibitors in breast cancer. N Engl J Med 2003;48:2431-42.
3. Reed MJ, Hutton JD, Baxendale PM, James VH, Jacobs HS, Fisher RP. The conversion of androstenedione to oestrone and production of oestrone in women with endometrial cancer. J Steroid Biochem 1979;11:905-11.
4. Thurlimann B, Keshaviah A, Coates AS, et al. A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer. N Engl J Med 2005;353:2747-57.
5. Amar S, Roy V, Perez EA. Letrozole: present and future role in the treatment of breast cancer. Expert Opin Pharmacother 2007;8:1965-75.
6. Taylor RE, Powles TJ, Humphreys J, et al. Effects of endocrine therapy on steroid-receptor content of breast cancer. Br J Cancer1982;45:80-5.
7. Reed MJ, Purohit A, Woo LWL, Potter BVL. The development of steroid sulphatase inhibitors. Endocr Relat Cancer1996;3:9-23.
8. Reed MJ, Purohit A, Woo LWL, Newman SP, Potter BVL. Steroid sulfatase: molecular biology, regulation, and inhibition. Endocr Rev 2005;26:171-202.
9. Falany JL, Falany CN. Expression of cytosolic sulfo-transferases in normal mammary epithelial cells and breast cancer cell lines. Cancer Res1996;56:1551-5.
10. Falany JL, Macrina N, Falany CN. Regulation of MCF-7 breast cancer cell growth by β-estradiol sulfonation. Breast Cancer Res Treat 2002;74:167-76.
11. Purohit A, Riaz AA, Ghilchik MW, Reed MJ. The origin of oestrone sulphate in normal and malignant breast tissues in postmenopausal women. Horm Metab Res 1992;24:532-6.
12. Thijssen JH. Local biosynthesis and metabolism of oestrogens in the human breast. Maturitas 2004;49:25-33.
13. Poulin R, Labrie F. Stimulation ofcell proliferation and estrogenic response by adrenal C19-Δ5-steroids in the ZR-75-1 human breast cancer cell line. Cancer Res1986;46:4933-7.
14. DauvoisS,Danielian PS, White R, Parker MG. Anti-estrogen ICI 164,384 reduces cellular estrogen receptor content by increasing its turnover. Proc Natl Acad Sci USA1992;89:4037-41.
15. Lonning PE, Dowsett M, Powles TJ. Postmenopausal estrogen synthesis and metabolism: alterations caused by aromatase inhibitors used for the treatment of breast cancer. J Steroid Biochem 1990;35:355-66.
16. Evans TR, Rowlands MG, Silva MC, Law M, Coombes RC. Prognostic significance of aromatase and estrone sulfatase enzymes in human breast cancer. J Steroid Biochem Mol Biol 1993;44:583-7.
17. Lipton A, Santen RJ, Santner SJ, Harvey HA,Sand-ers SI, Matthews YL. Prognostic value of breast cancer aromatase. Cancer1992;70:1951-5.
18. Evans TR, Rowlands MG, Law M, Coombes RC. Intratumoral oestrone sulphatase activity as a prognostic marker in human breast carcinoma. Br J Cancer 1994;69:555-61.
19. James VHT, McNeill JM, Lai LC, Newton CJ, Ghilchik MW, Reed MJ. Aromatase activity in normal breast and breast tumor tissue: in vivo and in vitro studies. Steroids1987;50:269-79.
20. Santner SJ, Feil RD, Santen RJ. In situ estrogen production via estrone sulphatase pathway in breast tumors: relative importance versus aromatase pathway. J Clin Endocrinol Metab 1984;54:29-33.
21. Jahanzeb M. Reducing the risk for breast cancer recurrence after completion of tamoxifen treatment in postmenopausal women. Clin Ther 2007;29:1535-47.
22. Dixon JM. Aromatase inhibitors in early breast cancer therapy: a variety of treatment strategies. Expert Opin Pharmacother 2006;7:2465-79.
23. Foster PA, Newman SP, Chander SK, et al. In vivo efficacy of STX213, a second-generation steroid sulfatase inhibitor, for hormone-dependent breast cancer therapy. Clin Cancer Res 2006;12:5543-9.
24. Foster PA, Chander SK, Parsons MF, et al. Efficacy of three potent steroid sulfatase inhibitors: pre-clinical investigations for their use in the treatment of hormone-dependent breast cancer. Breast Cancer Res Treat 2008;111:129-38.
25. Stanway S, Purohit A, Woo LWL, et al. Phase I study of STX 64 (667 Coumate) in breast cancer: the first study of a steroid sulfatase inhibitor. Clin Cancer Res 2006;12:1585-92.
26. Stanway SJ, Delavault P, Purohit A, et al. Steroid sulfatase: a new target for the endocrine therapy of breast cancer. Oncologist 2007;12:370-4.
27. Morphy R, Rankovic Z. Designed multiple ligands. An emerging drug discovery paradigm. J Med Chem 2005;48:6523-43.
28. Woo LWL, Sutcliffe OB, Bubert C, et al. First dual aromatase-sulfatase inhibitors. J Med Chem 2003; 46:3193-6.
29. Woo LWL, Bubert C, Sutcliffe OB, et al. Dual aromatase-steroid sulfatase inhibitors. J Med Chem 2007;50:3540-60.
30. Wood PM, Woo LWL, Humphreys A, et al. A letrozole-based dual aromatase-sulphatase inhibitor with in vivo activity. J Steroid Biochem Mol Biol 2005;94:123-30.
31. Jackson T, Woo LWL, Trusselle MN, et al. Dual aromatase-sulfatase inhibitors based on the anastrozole template: synthesis, in vitro SAR, molecular modelling and in vivo activity. Org Biomol Chem 2007;5: 2940-52.
32. Woo LWL, Purohit A, Malini B, Reed MJ, Potter BVL. Potent active site-directed inhibition of steroid sulphatase by tricyclic coumarin-based sulphamates. Chem Biol 2000;7:773-91.
33. Zhou DJ, Pompon D, Chen SA. Stable expression of human aromatase complementary DNA in mammalian cells: a useful system for aromatase inhibitor screening. Cancer Res 1990;50:6949-54.
34. Santner SJ, Chen S, Zhou D, Korsunsky Z, Martel J, Santen RJ. Effect of androstenedione on growth of untransfected and aromatase-transfected MCF-7 cells in culture. J Steroid Biochem Mol Biol 1993;44: 611-6.
35. Zhou D,Wang J, Chen E, Murai J, Siiteri PK, Chen S. Aromatase gene is amplified in MCF-7 human breast cancer cells. J Steroid Biochem Mol Biol 1993;46: 147-53.
36. Okada M, Yoden T, Kawaminami E, Shimada Y, Kudoh M, Isomura Y. Studies on aromatase inhibitors. II. Synthesis and biological evaluation of1-amino-1H-1,2,4-triazole derivatives. Chem Pharm Bull (Tokyo) 1997;45:333-7.
37. Purohit A, Williams GJ, Roberts CJ, Potter BVL, Reed MJ. In vivo inhibition of oestrone sulphatase and dehydroepiandrosterone sulphatase by oestrone-3-O-sulphamate. Int J Cancer 1995;63:106-11.
38. Seibert K, Shafie SM,TricheTJ, et al. Clonal variation ofMCF-7 breast cancer cells in vitro and in athymic nude mice. Cancer Res 1983;43:2223-39.
39. Brunner N, Spang-Thomsen M,Vindelov L,WolffJ, Engelholm SA. Effect of tamoxifen on the receptor-positiveT61 and the receptor-negativeT60 human breast carcinomas grown in nude mice. Eur J Cancer Clin Oncol 1985;21:1349-54.
40. Day JM,Tutill HJ, Newman SP, et al. 17β-Hydroxys-teroid dehydrogenase type 1 and type 2: association between mRNA expression and activity in cell lines. Mol Cell Endocrinol 2005;248:246-9.
41. Yue W, Brodie A. MCF-7 human breast carcinomas in nude mice as a model for evaluating aromatase inhibitors. J Steroid Biochem Mol Biol 1993;44:671-3.
42. Yue W, Zhou D, Chen S, Brodie A. A new nude mouse model for postmenopausal breast cancer using MCF-7 cells transfected with the human aromatase gene. Cancer Res 1994;54:5092-5.
43. Yue W, Wang J, Savinov A, Brodie A. Effect of aromatase inhibitors on growth of mammary tumors in a nude mouse model. Cancer Res 1995;55:3073-7.
44. Diver MJ, Hughes JG, Hutton JL,West CR, Hipkin LJ. The long-term stability in whole blood of14 commonly-requested hormone analytes. Ann Clin Biochem 1994;31:561-5.
45. McNeal C. Two targets, one drug for new EGFR inhibitors. J Natl Cancer Inst 2006;16:1102-3.
46. Chen S, Masri S, Wang X, Phung S,YuanY-C,Wu X. What do we know about the mechanisms of aromatase inhibitor resistance? J Steroid Biochem Mol Biol 2006;102:232-40.
47. Lu Q, Yue W, Wang J, Liu Y, Long B, Brodie A. The effects of aromatase inhibitors and antiestrogens in the nude mouse model. Breast Cancer Res Treat 1998;50:63-71.
48. Brodie A, Sabnis G, Macedo L. Xenograft models for aromatase inhibitor studies. J Steroid Biochem MolBiol2007;106:119-24.
49. Brodie A, Jelovac D, Macedo L, Sabnis G,Tilghman S, Goloubeva O. Therapeutic observations in MCF-7 aromatase xenografts. Clin Cancer Res 2005;11: 884-8s.